Global Crohns Disease Therapeutics Market 2023

The market for therapeutics to treat Crohns disease is projected to grow at a CAGR of 7.6% from 2023 to 2029, reaching USD 23.63 billion by 2029, compared to USD 13.86 billion in 2022. Crohns disease, an inflammatory bowel disease, causes digestive tract inflammation and symptoms like abdominal pain, severe diarrhea, and weight loss. The market is dominated by Crohns disease in the inflammatory bowel disease treatment sector. The US has the highest prevalence of Crohns disease, followed by the UK and China. The rising prevalence drives the markets growth. Over 100 assets are in development for Crohns disease, with most in Phase II. Anti-interleukin and integrin antibodies are the primary drugs in the pipeline. The US leads in global clinical trials. Biologics like anti-TNFs are widely used, but new therapies with better mechanisms of action and convenience are needed. Microbiome-based therapeutics show promise. Major companies invest in research, acquisitions, and collaborations. Multiple therapies have been launched, including Humira, Remicade, and Stelara. Five major companies have approved drugs for Crohns disease.

The report covers market size and growth, segmentation, competitive landscape, trends and strategies for global Crohns disease therapeutics market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors approaches.

Market Segmentation
The market is segmented based on various factors, including drug class, gender type, age group, disease type, and geography.
Drug class: 5-aminosalicylates, TNF-alpha inhibitors, others
Gender: men, women
Age group: 49 yrs. & below, 50 yrs. & above
Disease type: large intestinal type, small intestinal type, small/large intestinal type

Segmentation by Geography
North America US
Europe Germany, France, UK, Italy, Spain
APAC - China, Japan

TNF-Alpha inhibitors hold a significant share in the global Crohns disease therapeutics market, but other drug classes are expected to grow rapidly. Skyrizis approval will drive the market. New mechanisms of action are being researched to address non-response issues. Launch of new drugs for moderate-to-severe patients will contribute to market growth. Anti-integrin and interleukin inhibitors gain popularity. Women have a substantial presence. The small intestinal type grows fastest. Individuals aged 49 and below dominate. The US dominates, but the UK will grow rapidly. Biosimilars impact China and Japan.

Competitive Landscape
The Crohns disease treatment market is dominated by generic medication providers and selective pharmaceutical and biotechnology companies. Key companies in this market include AbbVie Inc., AstraZeneca plc, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celltrion, Inc., Johnson & Johnson (J&J), Redhill Biopharma Ltd., Takeda Pharmaceutical Company Limited, UCB SA, among others.

Recent Industry Developments
AbbVie achieved a significant milestone in June 2022 with the FDA approval of SKYRIZI (risankizumab-rzaa), the first and only IL-23 inhibitor for moderately to severely active Crohns disease (CD). The approval was based on positive results from the ADVANCE and MOTIVATE studies, which evaluated risankizumabs efficacy and safety in comparison to placebo.

In May 2022, AbbVie announced positive topline results from the Phase 3 U-ENDURE maintenance study, showing that upadacitinib demonstrated superior efficacy compared to placebo in achieving endoscopic response and clinical remission in patients with moderate to severe Crohns disease.

Ossium Health received FDA acceptance of its IND application for OSSM-001 in March 2022. OSSM-001, a mesenchymal stem cell product, aims to treat refractory perianal fistulas in Crohns disease patients. Ossium is now preparing for a Phase 1 clinical trial to evaluate the safety and efficacy of OSSM-001, expected to begin by the end of 2022.

Scope of the Report
To analyze and forecast the market size of the global Crohns disease therapeutics market.
To classify and forecast the global Crohns disease therapeutics market based on drug class, gender, age group, disease type, geography.
To identify drivers and challenges for the global Crohns disease therapeutics market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global Crohns disease therapeutics market.
To identify and analyze the profile of leading players operating in the global Crohns disease therapeutics market.

Why Choose This Report
Gain a reliable outlook of the global Crohns disease therapeutics market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

Companies Mentioned
AbbVie Inc., AstraZeneca plc, Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celltrion Inc., Johnson & Johnson (J&J), Redhill Biopharma Ltd., Takeda Pharmaceutical Company Limited, UCB SA

PART 1. INTRODUCTION
1.1 Description
1.2 Objectives of The Study
1.3 Market Segment
1.4 Years Considered for The Report
1.5 Currency
1.6 Key Target Audience
PART 2. RESEARCH METHODOLOGY
2.1 Primary Research
2.2 Secondary Research
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
4.1 Introduction
4.2 Drivers
4.3 Restraints
PART 5. GLOBAL CROHNS DISEASE THERAPEUTICS MARKET BY DRUG CLASS
5.1 5-aminosalicylates
5.2 TNF-alpha inhibitors
5.3 Others
PART 6. GLOBAL CROHNS DISEASE THERAPEUTICS MARKET BY GENDER
6.1 Men
6.2 Women
PART 7. GLOBAL CROHNS DISEASE THERAPEUTICS MARKET BY AGE GROUP
7.1 49 yrs. & below
7.2 50 yrs. & above
PART 8. GLOBAL CROHNS DISEASE THERAPEUTICS MARKET BY DISEASE TYPE
8.1 Large intestinal type
8.2 Small intestinal type
8.3 Small/large intestinal type
PART 9. GLOBAL CROHNS DISEASE THERAPEUTICS MARKET BY GEOGRAPHY
9.1 North America
9.2 Europe
9.3 APAC
PART 10. COMPANY PROFILES
10.1 AbbVie Inc.
10.2 AstraZeneca plc
10.3 Biogen Inc.
10.4 Boehringer Ingelheim International GmbH
10.5 Bristol-Myers Squibb Company
10.6 Celltrion, Inc.
10.7 Johnson & Johnson (J&J)
10.8 Redhill Biopharma Ltd.
10.9 Takeda Pharmaceutical Company Limited
10.10 UCB SA
DISCLAIMER

2024 Global Hepatitis Diagnostic Testing Markers Supplier Shares and Strategies Volume and Sales Segment Forecasts for Immunodiagnostic and Molecular Diagnostic Procedures--Hospitals Blood Banks Commercial Labs POC Locations

2024 Global Hepatitis Diagnostic Testing for 10 Markers: Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Immunodiagnostic and Molecular Diagnostic Procedures--Hospitals, Blood Banks, Commercial Labs, POC Locations The

USD 7500 View Report

2024 Global PSA Testing Market Supplier Shares and Strategies Volume and Sales Segment Forecasts Emerging Opportunities

2024 Global PSA Testing Market: US, Europe, Japan--Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Opportunities This unique report from provides information and analysis not available from any

USD 2450 View Report

Global CrohnS Disease Drug Industry Market Research Report

Based on the CrohnS Disease Drug industrial chain, this report mainly elaborate the definition, types, applications and major players of CrohnS Disease Drug market in details. Deep analysis about market

USD 2960 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available